On the stock market since 2010, it operates in the world of health and science. It has 14,042 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (1% a year).
The gap is $3.7B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 78% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.84 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 5% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 95 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, SARTF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SARTF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.